hydroxychloroquine - versus antiviral and associated therapy - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 4.93 [0.79, 30.65]< 10%2 studies (2/-)4.4 %some concernnot evaluable moderatecrucial-
clinical deterioration 1.07 [0.63, 1.82]< 10%1 study (1/-)40.2 %some concernnot evaluable moderateimportant-
hospital discharge 0.91 [0.54, 1.54]> 10%1 study (1/-)36.2 %some concernnot evaluable moderateimportant-
ICU admission 3.94 [0.78, 19.87]< 10%1 study (1/-)4.9 %some concernnot evaluable moderatenon important-

safety endpoints 00

arrhythmia 1.02 [0.02, 52.25]< 10%1 study (1/-)49.6 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.